CDKN1A and familial pancreatic carcinoma: Because USP22 upregulated p21 expression via PTEN‐MDM2‐p53 signaling in pancreatic cancer, we hypothesized that the combination of USP22 overexpression and MDM2 inhibitor treatment would have an enhanced antipancreatic cancer effect.